濮阳东方男科医院收费比较低濮阳东方男科在线免费咨询,濮阳东方男科评价好不好,濮阳东方妇科网络预约,濮阳东方医院割包皮评价很高,濮阳东方男科医院割包皮手术评价,濮阳东方医院男科治疗阳痿收费公开,濮阳东方医院妇科技术非常专业

New York, Sept. 23 (Xinhua) -- A Chinese scientist was presented a prestigious U.S. award on Friday for the discovery of artemisinin, a drug therapy for malaria that has saved millions of lives across the globe, especially in the developing world.Pharmacologist Tu Youyou, 81, became the first scientist on the Chinese mainland to win Lasker Award, known as "America's Nobels" for their knack of gaining future recognition by the Nobel committee.Tu, a scientist at the China Academy of Chinese Medical Sciences in Beijing, pioneered a new approach to malaria treatment that has benefited hundreds of millions of people and promises to benefit many times more. By applying modern techniques and rigor to a heritage provided by 5000 years of Chinese traditional practitioners, she has delivered its riches into the 21st century."Not often in the history of clinical medicine can we celebrate a discovery that has eased the pain and distress of hundreds of millions of people and saved the lives of countless numbers of people, particularly children, in over 100 countries," Lucy Shapiro, a member of the award jury and professor of Stanford University, said while describing Tu' s discovery.Shapiro said the discovery, chemical identification, and validation of artemisinin, a highly effective anti-malarial drug, is largely due to the "scientific insight, vision and dogged determination" of Professor Tu and her team. She thought Professor Tu's work has provided the world with arguably the most important pharmaceutical intervention in the last half century."The discovery of artemisinin is a gift to mankind from traditional Chinese medicine," Tu said while receiving the award. "Continuous exploration and development of traditional medicine will, without doubt, bring more medicines to the world."

WASHINGTON, Sept. 14 (Xinhua) -- Controlling diabetes may someday involve mining stem cells from the lining of the uterus, Yale School of Medicine researchers report in a new study published Wednesday in the journal Molecular Therapy. The team treated diabetes in mice by converting cells from the uterine lining into insulin-producing cells.The endometrium or uterine lining, is a source of adult stem cells. These cells generate uterine tissue each month as part of the menstrual cycle. Like other stem cells, however, they can divide to form other kinds of cells.Led by Yale Professor Hugh Taylor, the researchers bathed endometrial stem cells in cultures containing special nutrients and growth factors. Responding to these substances, the endometrial stem cells adopted the characteristics of beta cells in the pancreas that produce insulin. Over the course of a three- week incubation process, the endometrial stem cells took on the shape of beta cells and began to make proteins typically made by beta cells. Some of these cells also produced insulin.After a meal, the body breaks food down into components like the sugar glucose, which then circulates in the blood. In response, beta cells release insulin, which allows the body's cells to take in the circulating glucose. In this study, Taylor and his team exposed the mature stem cells to glucose and found that, like typical beta cells, the cultured cells responded by producing insulin. The team then injected diabetic mice with the mature, insulin-making stem cells. The mice had few working beta cells and very high levels of blood glucose.Mice that did not receive the stem cell therapy continued having high blood sugar levels, developed cataracts and were lethargic. In contrast, mice that received the cell therapy were active and did not develop cataracts, but the animals' blood sugar levels remained higher than normal.The Yale team's findings suggest that endometrial stem cells could be used to develop insulin-producing islet cells, which are found in the pancreas. These islet cells could then be used to advance the study of islet cell transplantation to treat people with diabetes.Taylor said in a statement that the next step in the research will be to verify how long this treatment remains effective.

BEIJING, July 15 (Xinhua) -- The Chinese Academy of Agricultural Sciences (CAAS) announced Friday that a group of international scientists has finished sequencing the genetic code of the potato.The Potato Genome Sequencing Consortium (PGSC), which is led by Chinese scientists and made up of 97 researchers from 14 countries, has sequenced the complete potato genome and published a report of its findings in the latest issue of the scientific journal Nature, said the CAAS.The research took six years and revealed that the potato contains about 39,000 genes, said the CAAS.Qu Dongyu, a potato farming specialist with the Crop Science Society of China and a promoter of the PGSC, said the study helped discover genes that define the growth and insect resistance of potatoes.The sequenced genome will enable scientists to create new varieties of potato that are high in yield and quality and more resistant to insects and diseases, he said.Huang Sanwen, a researcher with the CAAS and one of the three corresponding authors of the report, said the sequencing will also allow potato breeders to accelerate the breeding process of new seeds from 10 to 12 years to about 5 years.China is the world's top potato grower, with its farmers planting potatoes on nearly 90 million mu (6 million hectares) of land each year. The average yield per mu stands at 1,000 kg, only one-third of that harvested by countries with advanced technologies, Qu said.

WASHINGTON, July 20 (Xinhua) -- The loss of a protein that coats sperm may explain a significant proportion of infertility in men worldwide, according to a study by an international team of researchers led by University of California Davis.A paper describing the work was published Wednesday in the journal Science Translational Medicine. The research could open up new ways to screen and treat couples for infertility.The gene DEFB126 encodes a protein called Beta Defensin 126, which coats the surface of sperm and helps it penetrate cervical mucus in the female. A survey of samples from the U.S., Britain and China showed that as many as a quarter of men worldwide carry two copies of the defective gene.In the new study, researchers found that men with a muted DEFB126 lack Beta Defensin 126, making it much more difficult for sperm to swim through the mucus and eventually join with an egg.Examining 500 newly married Chinese couples, researchers found that the lack of Beta Defensin 126 in men with the DEFB126 mutation lowered fertility (even among men that did not display other deficiencies usually associated with infertility, like inadequate semen volume and low sperm motility). Wives of men with the Beta Defensin 126 variant were significantly less likely to become pregnant than were other couples, and 30 percent less likely to have a birth.This genetic variation in DEFB126 likely accounts for many unexplained cases of infertility, researchers say. They hope next to work with a major infertility program in the U.S. to further explore the role of the mutation.

BEIJING, June 29 (Xinhuanet) -- Twitter Inc. co-founders Biz Stone and Evan Williams said they are moving on from the microblogging service, media reports said Wednesday.“The Twitter crew and its leadership team have grown incredibly productive,” Stone said on the blog. “I’ve decided that the most effective use of my time is to get out of the way until I’m called upon to be of some specific use.”The two will continue to advise Twitter on strategic matters, but devote the lions' share of their time to The Obvious Corporation, Stone said.Obvious was first created by Williams to buy back a company from investors that he and Stone failed to sell about six years ago, Stone said. The two began working together after leaving Google in 2005.The company will also be run by Jason Goldman, a former Twitter executive, Stone said.